Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05396248
Other study ID # R-1183-22
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 28, 2023
Est. completion date March 2027

Study information

Verified date March 2024
Source Kessler Foundation
Contact Nancy Moore
Phone 1973-324-8450
Email nbmoore@kesslerfoundation.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in individuals with Mild Cognitive Impairment (MCI). Impairment in higher level cognitive processing, such as new learning and memory, is one of the most common deficits in individuals with MCI and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. Despite these findings, few studies have attempted to treat these cognitive deficits in order to improve the everyday functioning of individuals with MCI. Through a small randomized clinical trial, the investigators found that individuals with MCI with documented cognitive impairment show a significant improvement in their memory performance following a treatment protocol designed to facilitate learning. The current proposal will replicate this finding and further evaluate (a) the impact of the treatment on everyday functioning, (b) the long term efficacy of the treatment and (c) the utility of booster sessions in facilitating long-term treatment effects. We will randomly assign older individuals who meet criteria for a diagnosis of amnestic MCI to a memory retraining group or a placebo control group. Both groups will undergo baseline, immediate and long-term follow-up assessment consisting of: (1) a traditional neuropsychological battery, (2) an assessment of global functioning examining the impact of the treatment on daily activities, and (3) functional neuroimaging. This design will allow the investigators to evaluate the efficacy of this particular memory retraining technique in an aMCI population through the assessment of cognitive function via a standard evaluation. In addition, the investigators will be able to draw conclusions regarding the impact of this particular memory remediation program on everyday life from questionnaires completed by the participant and a significant other. Optional enrollment in pre- post neuroimaging will also allow the investigators to look at changes in the brain.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 2027
Est. primary completion date March 2027
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - 60 or older. - read and speak English fluently. - Research based diagnosis of Amnestic Mild Cognitive Impairment Exclusion Criteria: - prior stroke or neurological injury/disease (i.e. traumatic brain injury, Multiple Sclerosis, or Stroke). - history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis). - significant alcohol or drug abuse history (inpatient treatment). - Benzodiazepines and steroid use

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Memory Retraining Exercises
Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Placebo Control Memory Exercises
Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Kessler Foundation Research Center West Orange New Jersey

Sponsors (3)

Lead Sponsor Collaborator
Kessler Foundation Michigan State University, University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Verbal list learning Change in total score from Open-Trial Selective Reminding Test (OT-SRT) four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Primary Participation in everyday life Change in total score from Participation Assessment with Recombined Tools four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Self-reported depression Change in total score on the Geriatric Depression Scale four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Self-reported anxiety Change in total score on the Geriatric Anxiety Scale four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Self-reported quality of life Change in total score on the Quality of Life in Alzheimer's Disease four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Self-reported quality of well-being Change in total score on the Quality of Well-Being Scale - Self-Administered four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Functional neuroimaging Change in total scores from memory task during fMRI scan two points in time: pre-treatment and immediately following treatment
Secondary Functional memory Change in total score from Object Location Task four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Functional memory Change in total score from the modified Everyday Memory Scenarios (EMS) four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
Secondary Story memory Change in total score from Prose Memory Test four points in time: pre-treatment, immediately following treatment, and 6- and 18- months after treatment is completed
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A